23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,
23andMe is laying off 40 percent of its staff
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs will impact 40 percent of the genetic testing company’s workforce. 23andMe CEO and co-founder Anne Wojcicki said in a statement released on Monday that the staff reduction would save the beleaguered company more than $35 million.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
Hosted on MSN8h
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our ...
Rolling Out4h
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...
Orange County Register4h
Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was “taking these difficult but ...
Yahoo6h
23andMe to Cut 40% of Its Staff Amid Grim Financials
But in announcing the cuts, 23andMe CEO Anne Wojcicki said her goal is to ensure the "long-term success" of its core ...
Benzinga.com13h
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
Pittsburgh Post-Gazette on MSN6d
Nila Bala: The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...